Well, certainly, there is a need to examine the current system in terms of whether there should be a national panel or local panels for individual patient funding requests—we’re open to that—and, of course, the use of the word ‘exceptionality’. There has to be something, otherwise there would be difficulties in terms of determining how drugs would be allocated, but, without prejudging anything, we enter this with an open mind. We take on board the views of others who say that it is difficult where you have a situation where somebody in one part of Wales can access a drug and someone in another part of Wales can’t. Clearly, that’s a very difficult position to defend and that’s why, of course, in accordance with the spirit and the terms of the agreement, this is something that we’re looking to revisit.